Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 4/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2408233 | 0.98 | ACP3 (0.46) | ACP3TRPA1SRCPOLBCYP2D6 | |
| SCHEMBL2174320 | 0.87 | ACP3 (0.45) | ACP3TRPA1SRCPOLBCYP2D6 | |
| SCHEMBL2352723 | 0.85 | ACP3 (0.46) | ACP3SRCPOLBCYP2D6 | |
| SCHEMBL2248870 | 0.84 | ACP3 (0.43) | ACP3POLBCYP2D6 | |
| SCHEMBL31315617 | 0.84 | ACP3 (0.50) | ACP3SRCPOLBCYP2D6LMNA | |
| Hydrogen Peroxide SCHEMBL8609521 | 0.84 | ACP3 (0.50) | ACP3SRCPOLBCYP2D6LMNA | |
| Hydrochloric Acid SCHEMBL2392993 | 0.83 | ACP3 (0.45) | ACP3SRCPOLBCYP2D6 | |
| SCHEMBL2173897 | 0.83 | ACP3 (0.45) | ACP3TRPA1SRCCYP2D6ALDH1A1 | |
| SCHEMBL2392797 | 0.83 | ACP3 (0.45) | ACP3SRCPOLBCYP2D6 | |
| SCHEMBL2408234 | 0.80 | ACP3 (0.41) | ACP3TRPA1SRCPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614267-B2 | Method for producing mono-hydroxyfunctionalized dialkylphosphinic acids and esters and salts thereof by means of allyl alcohols and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2013-12-24 | — | — | US | disclosed |
| EP-2352735-B1 | METHOD FOR PRODUCING MONO-HYDROXYFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ALLYL ALCOHOLS AND USE THEREOF | CLARIANT FINANCE BVI LTD (VG) | 2013-12-11 | — | — | EP | disclosed |
| EP-2367834-B1 | METHOD FOR PRODUCING MONO-HYDROXYFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ACROLEINS AND USE THEREOF | CLARIANT FINANCE BVI LTD (VG) | 2013-12-11 | — | — | EP | disclosed |
| US-8604108-B2 | Method for producing mono-hydroxyfunctionalized dialkylphosphinic acids and esters and salts thereof by means of acroleins and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2013-12-10 | — | — | US | disclosed |
| EP-2367834-A1 | METHOD FOR PRODUCING MONO-HYDROXYFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ACROLEINS AND USE THEREOF | Clariant International Ltd. (CH) | 2011-09-28 | — | — | EP | disclosed |
| US-20110224339-A1 | Method for Producing Mono-Hydroxyfunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof By Means of Acroleins and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-15 | — | — | US | disclosed |
| US-20110213062-A1 | Method for Producing Mono-Hydroxyfunctionalized Dialkyphosphinic Acids and Esters and Salts Thereof and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-01 | — | — | US | disclosed |
| US-20110201733-A1 | Method for Producing Mono-Hydroxyfunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof By Means of Allyl Alcohols and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-08-18 | — | — | US | disclosed |
| EP-2352735-A1 | METHOD FOR PRODUCING MONO-HYDROXYFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ALLYL ALCOHOLS AND USE THEREOF | Clariant International Ltd. (CH) | 2011-08-10 | — | — | EP | disclosed |
| EP-2346886-A1 | METHOD FOR PRODUCING MONO-HYDROXYFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF AND USE THEREOF | Clariant Finance (BVI) Limited (VG) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010051885-A1 | METHOD FOR PRODUCING MONO-HYDROXYFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ACROLEINS AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010051884-A1 | METHOD FOR PRODUCING MONO-HYDROXYFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ALLYL ALCOHOLS AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010051889-A1 | METHOD FOR PRODUCING MONO-HYDROXYFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213062-A1 | Method for Producing Mono-Hydroxyfunctionalized Dialkyphosphinic Acids and Esters and Salts Thereof and Use Thereof | HAO2, HACL2, ACSL3 | ACP3 1325/4885TRPA1 4115/4885SRC 360/4885 |
| US-20110224339-A1 | Method for Producing Mono-Hydroxyfunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof By Means of Acroleins and Use Thereof | HAO2, AOC3, AOC2 | ACP3 808/4885TRPA1 2671/4885SRC 547/4885 |
| US-20110201733-A1 | Method for Producing Mono-Hydroxyfunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof By Means of Allyl Alcohols and Use Thereof | HAO2, ALOX5, AOC3 | ACP3 1345/4885TRPA1 3460/4885SRC 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.